Posted by Michael Wonder on 31 May 2026
MannKind announces FDA approval of Afrezza, the first and only inhaled mealtime insulin for use in children and adolescents aged 6 and older living with diabetes
29 May 2026 - Eligible patients can access Afrezza today for $35 or less per month, with dedicated support through MannKind Cares.
MannKind Corporation today announced that the US FDA has approved Afrezza (insulin human) inhalation powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.
